|
|
Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data CollectionOAKVILLE, ON / ACCESSWIRE / April 21, 2022 / NeonMind Biosciences Inc. CSE:NEONOTCQB:NMDBDFRA:6UF "NeonMind or the "Company", announced today it has advanced its strategy to streamline access to tr... Lire le communiqué |
|
| |
|
| |
|
|
Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical EducationOAKVILLE, ON / ACCESSWIRE / April 19, 2022 / NeonMind Biosciences Inc. CSE:NEONOTCQB:NMDBDFRA:6UF "NeonMind or the "Company", an integrated drug development and wellness company focused on bringing innovative psychedelicbased treatments to people suffering from obes... Lire le communiqué |
|
| |
|
| |
|
|
Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMindbranded Specialty Mental Health Clinics Across CanadaOAKVILLE, ON / ACCESSWIRE / April 12, 2022 / NeonMind Biosciences Inc. CSE:NEON OTCQB:NMDBF FRA:6UF "NeonMind or the "Company", an integrated drug development and wellness company focu... Lire le communiqué |
|
| |
|
| |
|
|
To Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic LicensingOAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. CSE:NEONOTCQB:NMDBFFRA:6UF "NeonMind or the "Company", an integrated drug development and wellness company focused on b... Lire le communiqué |
|
| |
|
| |
|
|
Data Further Validates Psilocybin as a Drug Candidate for Obesity and Supports Development of NeonMinds Drug Programs NEO001 and NEO002OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. CSE:NEONOTCQB:NMDBFFRA:6UF "NeonMind or the "Company", an integrated drug development and wellness company focused on bringing innovative psychedelicbased treatments to peop... Lire le communiqué |
|
| |
|
| |
|
|
OAKVILLE, ON / ACCESSWIRE / March 22, 2022 / NeonMind Biosciences Inc. CSE:NEONOTCQB:NMDBFFRA:6UF "NeonMind or the "Company", an integrated drug development and wellness company focused on bringing innovative psychedelicbased treatments to people suffering from obesity and mental health disorders, announced today it has filed a new patent application with the... Lire le communiqué |
|
| |
|
| |
|
|
Completed concrete milestones in its strategy to become a leading psychedelic drug developer and specialty clinics operator. Developed clear drug development pathway for NEO001, the industrys first psilocybinbased obesity treatment with nearterm clinical milestones. Partnered with wellestablished specialty treatment providers, SRx Health Solutions and BioScript Solutions to build out a network of... Lire le communiqué |
|
| |
|
| |
